

## "COMMENTARY"

## Open Access

# Methylhonokiol attenuates neuroinflammation: a role for cannabinoid receptors?

Jürg Gertsch<sup>1\*</sup> and Sharon Anavi-Goffer<sup>2</sup>**Abstract**

The cannabinoid type-2 G protein-coupled (CB<sub>2</sub>) receptor is an emerging therapeutic target for pain management and immune system modulation. In a mouse model of Alzheimer's disease (AD) the orally administered natural product 4'-O-methylhonokiol (MH) has been shown to prevent amyloidogenesis and progression of AD by inhibiting neuroinflammation. In this commentary we discuss an intriguing link between the recently found CB<sub>2</sub> receptor-mediated molecular mechanisms of MH and its anti-inflammatory and protective effects in AD animal models. We argue that the novel cannabimimetic MH may exert its beneficial effects via modulation of CB<sub>2</sub> receptors expressed in microglial cells and astrocytes. The recent findings provide further evidence for a potential role of CB<sub>2</sub> receptors in the pathophysiology of AD, spurring target validation and drug discovery.

**Keywords:** Alzheimer's disease, Cannabinoids, CB<sub>2</sub> receptors, Endocannabinoid System, *Magnolia grandiflora*, Medicinal plant, Methylhonokiol

**Background**

In a recent study published in *Journal of Neuroinflammation* Lee and colleagues report that the natural product 4'-O-methylhonokiol (MH) from *Magnolia grandiflora* L. potently inhibits lipopolysaccharide (LPS)-induced amyloidogenesis via anti-inflammatory mechanisms [1]. They have shown that chronic oral administration of 1 mg/kg of MH in mice strongly ameliorates LPS-induced memory impairment via inhibition of nuclear factor kappa B (NF-κB) and the gene expression of inducible nitric oxide synthase and cyclooxygenase-2. MH also inhibited the activation of astrocytes in the brain. The same group recently reported that MH attenuates the development of Alzheimer's disease (AD) in Tg2576 mice [2], and inhibits different signaling cascades related to oxidative stress and mitogen-activated protein (MAP) kinases [3-5]. In the European patent application EP2327402A2 by Bioland Ltd. the authors report the invention of a method for treating or preventing amyloid-related diseases comprising administering a pharmaceutically effective dosage of MH or pharmaceutically

acceptable salt thereof [6]. In this patent it is mentioned that MH inhibits acetylcholinesterase (AChE) and in a subsequent study it was shown that MH inhibits AChE activity at nM concentrations *in vitro* [7]. In yet another study by the same group, MH was shown to inhibit hydrogen peroxide and Aβ(1-42)-induced neurotoxicity in cultured neurons, as well as PC12 cells, by prevention of the reactive oxygen species generation and directly inhibited β-secretase activity and Aβ fibrilization *in vitro* [8]. Thus, MH could be a useful agent to prevent the neuroinflammation-associated pathogenesis or the progression of AD. However, beyond the AChE inhibition, none of the studies describe any molecular interaction of MH and its anti-inflammatory mechanism of action therefore remains elusive. In their article, Lee *et al.* suggested that inhibition of NF-κB and MAP kinases or the general antioxidative properties of MH are potential mechanisms by which this biphenyl natural product inhibits inflammation and amyloidogenesis [1]. However, from the data presented it is not clear whether the inhibition of signaling is a primary or secondary event, for example to receptor modulation. Moreover, some signaling effects were only observed at high nM or even μM concentrations *in vitro* which do not necessarily reflect the physiological concentrations in the brain. We therefore comment on a recently discovered molecular mechanism

\* Correspondence: [gertsch@ibmm.unibe.ch](mailto:gertsch@ibmm.unibe.ch)

<sup>1</sup>Institute of Biochemistry and Molecular Medicine, National Centre of Competence in Research NCCR TransCure, University of Bern, Bülhstrasse 28, Bern CH-3012, Switzerland

Full list of author information is available at the end of the article

of action of MH that could well explain some of the anti-inflammatory effects observed.


### **MH is a novel modulator of CB<sub>2</sub> receptors and inflammation**

In a previous study we have shown that MH is a potent and selective cannabinoid type-2 G protein-coupled (CB<sub>2</sub>) receptor ligand (*h*CB<sub>2</sub>  $K_i = 44$  nM), triggering a novel type of heteroactive signaling ( $EC_{50} \sim 10$  nM) [9]. In an *in vitro* profiling comprising more than 40 receptors MH was highly specific towards cannabinoid CB<sub>2</sub> receptors at nM concentrations. Furthermore, MH did not interact with cannabinoid type-1 (CB<sub>1</sub>) receptors, which in the brain are predominantly expressed in neurons, and found in presynaptic sites of GABAergic and glutamatergic synapses where they in a retrograde manner inhibit the release of these neurotransmitters [10-12]. Whereas CB<sub>1</sub> receptors mainly mediate the central side effects of cannabinoids, CB<sub>2</sub> receptors are primarily associated with a broad range of inflammatory processes [13-16]. CB<sub>2</sub> receptors are largely absent in the central nervous system (CNS) under normal conditions, but are upregulated in microglial cells and astrocytes under neuroinflammatory stimulation as it occurs in AD [17,18]. Indeed, CB<sub>2</sub> receptors appear to mediate many of the anti-inflammatory actions of endocannabinoids, the arachidonic acid-derived lipids which non-specifically target cannabinoid receptors [19,20]. There is an overall agreement that endocannabinoids are released during oxidative and inflammatory stress and counterbalance inflammation by inducing a TH<sub>1</sub>-TH<sub>2</sub> cytokine shift, although the exact mechanisms are not understood [14,21,22]. In our study we have shown that MH potently inhibits LPS-stimulated TNF- $\alpha$  expression and chemotaxis in macrophages in an apparently CB<sub>2</sub> receptor-dependent manner, exerting anti-inflammatory and anti-osteoclastogenic effects [9].

### **A role for CB<sub>2</sub> receptors in the pathophysiology of AD**

The report by Lee *et al.* [1] is interesting because it links MH with the already established anti-inflammatory effects mediated via CB<sub>2</sub> receptors in the brain. Since MH can act as both inverse agonist and agonist, depending on the specific signal pathway [9], it will be interesting to study the potentially positive and negative roles of CB<sub>2</sub> receptor signal transduction in models of AD. A prominent effect of MH is the inhibition of macrophage migration induced by the endocannabinoid 2-arachidonoyl glycerol (2-AG), even though MH shows anti-inflammatory properties similar to 2-AG and other endocannabinoids [9]. Interestingly, the CB<sub>2</sub> receptor mediates myeloid progenitor cell trafficking in the CNS, thus controlling inflammation in the brain [23]. The novel functionally heteroactive (dualistic) CB<sub>2</sub> receptor

ligand MH thus both inhibits and mimics the action of 2-AG via different pathways. Of note, 2-AG is the major arachidonic acid metabolite in the brain and a key lipid of the leukotriene network in the CNS [24]. It decreases brain edema, inflammation and infarct volume and improves clinical recovery via cannabinoid receptors [25,26]. Like 2-AG, MH can trigger calcium signaling in myeloid cells in a CB<sub>2</sub> receptor-dependent manner [9]. Intriguingly, in this context, CB<sub>2</sub> receptors have been directly associated with AD. It was shown that the activation of CB<sub>2</sub> receptors stimulates *in situ* and *in vitro*  $\beta$ -amyloid removal by human macrophages [27]. Cannabinoids acting at CB<sub>2</sub> receptors block  $\beta$ -amyloid-induced activation of cultured microglial cells and abrogate microglia-mediated neurotoxicity after  $\beta$ -amyloid addition to rat cortical co-cultures [28]. Furthermore, increased CB<sub>2</sub> receptor expression was also found in neuritic plaque-associated astrocytes and microglia in brains from patients with AD [29]. Since endocannabinoids negatively regulate TNF- $\alpha$ , the downregulation via CB<sub>2</sub> receptors may be a primary mechanism leading to inhibition of the downstream events including NF- $\kappa$ B activation, nitric oxide production and leukotriene synthesis [30,31]. Unfortunately, the role of endocannabinoids appears to be more complex because these promiscuous lipids also interact with other targets, such as peroxisome proliferator-activated receptors and the vanilloid receptor 1, which mediate the  $\beta$ -amyloid induced neuroinflammation in mice lacking the enzyme fatty acid amide hydrolase which regulates the metabolism of the endocannabinoid anandamide and other fatty acid ethanolamides [32]. Thus, agents selectively targeting CB<sub>2</sub> receptors could be more advantageous to treat AD. We speculate that several of the downstream signaling effects of MH as reported by Lee *et al.* [1] are mediated via CB<sub>2</sub> receptors. Along this line, the inhibition of I $\kappa$ -B $\alpha$  phosphorylation in microglial cells by anandamide can be reversed by SR144528, a CB<sub>2</sub> receptor-selective antagonist [33]. However, the synthetic cannabinoid WIN55212-2, a relatively potent non-selective CB<sub>1</sub>/CB<sub>2</sub> receptor agonist, has been shown to inhibit NF- $\kappa$ B in neuronal cells in a receptor-independent manner, albeit at high concentrations [34]. Thus, MH may well inhibit NF- $\kappa$ B via CB<sub>2</sub> receptors at nM concentrations, or at higher  $\mu$ M concentrations independently of receptor activation. CB<sub>2</sub> receptor activation may change the cytokine pattern and shift the polarization of the microglia towards M2, thus reprogramming macrophages for  $\beta$ -amyloid removal (Figure 1). An obvious way to assess the involvement of CB<sub>2</sub> receptors in the attenuation of neuroinflammation by MH would be to use CB<sub>2</sub> receptor knockout mice. Alternatively, the effects of MH may be directly compared to the effects of honokiol, which is the



biosynthetic precursor of MH that also targets kinases and NF- $\kappa$ B, exerting a range of anti-inflammatory effects *in vitro* at higher  $\mu$ M concentrations [35,36], but lacks the potent CB<sub>2</sub> receptor affinity [9]. Both strategies might be used to assess the relative contributions of each action, namely the CB<sub>2</sub> receptor modulation, general antioxidative effects or direct inhibition of kinases and NF- $\kappa$ B.

## Discussion

### The endocannabinoid system and neuroinflammation

Although AD is currently treated with cholinergic and glutamatergic therapies, which provide symptomatic benefit, the pathophysiology of AD is also widely associated with inflammation and aberrations of innate immunity [37]. Inflammation is not only involved in acute CNS conditions, such as stroke and traumatic injury, but it is also a central factor in chronic and neurodegenerative conditions such as AD, Parkinson's disease and multiple sclerosis [38]. Nevertheless, the inflammation hypothesis of AD, as attractive as it appears, has not yet been corroborated in clinical trials. Recent attempts to treat AD with non-steroidal anti-inflammatory drugs

and the TNF- $\alpha$  blocker entanercept were not successful [38,39], most probably due to the fundamental biochemical differences between neuroinflammation and peripheral inflammation [40]. However, novel pleiotropic anti-inflammatory mechanisms based on modulation of innate immunity, including the modulation of the endocannabinoid system, may be exploited. Because the CB<sub>2</sub> receptor mediates different anti-inflammatory effects via multiple signaling pathways [22] it was previously suggested to be a drug target to treat neurodegenerative diseases [17,31]. However, to date only few preclinical studies have explored the pharmacological effects of the distinctly different CB<sub>2</sub> receptor ligands (full agonists, partial agonists, inverse agonists, silent antagonists and protean agonists) in models of neuroinflammation and AD.

### CB<sub>2</sub> receptor modulation by MH to target AD?

The promising preclinical results obtained with the novel CB<sub>2</sub> receptor ligand MH may spur further research on the role of CB<sub>2</sub> receptors in neuroinflammation in general and AD in particular. The findings reported by Lee *et al.* [1] are intriguing because they

clearly indicate that MH is orally bioavailable to the CNS in mice, as well as active at relatively low doses. This is unexpected given the likely detoxification and phase II biotransformation of the biphenyl scaffold of this neolignan [41]. Thus, until the pharmacokinetics and metabolism of MH are studied it cannot be excluded that MH may potentially also act as a prodrug. Alternatively, MH crosses the blood–brain barrier and reaches the nM concentrations necessary to inhibit AChE and to modulate CB<sub>2</sub> receptors, thus exerting a polypharmacological action on acetylcholine levels and inflammation. In addition to downregulating cyclooxygenase-2 gene expression [1], MH also directly inhibits COX1/2 [42], which may further contribute to its *in vivo* efficacy. MH is a relatively rare natural product of plant origin which is mainly found in the seeds of *M. grandiflora*, a tree native to Northern Mexico and the USA [43,44]. Its long use in traditional medicine and its mention in the United States Pharmacopoeia as antimalarial and diaphoretic [44,45] suggest a lack of acute toxicity of MH, a major secondary metabolite in this medicinal plant.

## Conclusions

Because of the promising preclinical studies reported in the past, further studies are indicated to explore the therapeutic potential of CB<sub>2</sub> receptor modulators such as MH and its CB<sub>2</sub> receptor active derivatives [9] for AD drug discovery.

## Abbreviations

2-AG: 2-arachidonoyl glycerol; AChE: Acetylcholinesterase; AD: Alzheimer's disease; CB<sub>1</sub>: Cannabinoid type-1 receptor; CB<sub>2</sub>: Cannabinoid type-2 G protein-coupled receptor; CNS: Central nervous system; GABA: Gamma-aminobutyric acid; LPS: Lipopolysaccharide; MAPK: Mitogen-activated protein kinases; MH: O-methylhonokiol; NF-κB: Nuclear factor kappa B; TNF-α: Tumor necrosis factor alpha.

## Competing interests

The authors declare no conflict of interests.

## Acknowledgements

We thank Stefanie Hofer-Reyes for proofreading the manuscript.

## Author details

<sup>1</sup>Institute of Biochemistry and Molecular Medicine, National Centre of Competence in Research NCCR TransCure, University of Bern, Bülhstrasse 28, Bern CH-3012, Switzerland. <sup>2</sup>Departments of Behavioral Sciences and Molecular Biology, Ariel University Centre of Samaria, Ariel 40700, Israel.

## Authors' contributions

JG has written the commentary and drawn the figure. SAG has revised and complemented the commentary. Both authors read and approved the final manuscript.

## Authors' information

JG is a professor and research PI at the Institute of Biochemistry and Molecular Medicine (IBMM), National Centre of Competence in Research NCCR TransCure, University of Bern, Switzerland. His research interests focus on the endocannabinoid system, molecular pharmacology and chemical biology, with an interest in natural products and drug discovery. SAG is a senior researcher and lecturer at the Departments of Behavioral Sciences and Molecular Biology, Ariel University Centre of Samaria, Israel. Her current

research interests focus on the role of the endocannabinoid system in behavior and molecular pharmacology.

Received: 3 April 2012 Accepted: 23 May 2012

Published: 20 June 2012

## References

1. Lee YJ, Choi DY, Choi IS, Kim KH, Kim YH, Kim HM, Lee K, Cho WG, Jung JK, Han SB, Han JY, Nam SY, Yun YW, Jeong JH, Oh KW, Hong JT: **Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB *in vitro* and *in vivo* models.** *J Neuroinflammation* 2012, **9**:35.
2. Lee YJ, Choi DY, Lee YK, Lee YM, Han SB, Kim YH, Kim KH, Nam SY, Lee BJ, Kang JK, Yun YW, Oh KW, Hong JT: **4-O-methylhonokiol prevents memory impairment in the Tg2576 Transgenic Mice Model of Alzheimer's disease via regulation of β-Secretase activity.** *J Alzheimers Dis* 2012, **29**:677–690.
3. Choi IS, Lee YJ, Choi DY, Lee YK, Lee YH, Kim KH, Kim YH, Jeon YH, Kim EH, Han SB, Jung JK, Yun YP, Oh KW, Hwang DY, Hong JT: **4-O-methylhonokiol attenuated memory impairment through modulation of oxidative damage of enzymes involving amyloid-β generation and accumulation in a mouse model of Alzheimer's disease.** *J Alzheimers Dis* 2011, **27**:127–141.
4. Lee YJ, Choi IS, Park MH, Lee YM, Song JK, Kim YH, Kim KH, Hwang DY, Jeong JH, Yun YP, Oh KW, Jung JK, Han SB, Hong JT: **4-O-Methylhonokiol attenuates memory impairment in presenilin 2 mutant mice through reduction of oxidative damage and inactivation of astrocytes and the ERK pathway.** *Free Radic Biol Med* 2011, **50**:66–77.
5. Lee YK, Choi IS, Ban JO, Lee HJ, Lee US, Han SB, Jung JK, Kim YH, Kim KH, Oh KW, Hong JT: **4-O-methylhonokiol attenuated β-amyloid-induced memory impairment through reduction of oxidative damages via inactivation of p38 MAP kinase.** *J Nutr Biochem* 2011, **22**:476–486.
6. <http://worldwide.espacenet.com/publicationDetails/originalDocument?CC=EP&NR=2327402&KC=&FT=E>.
7. Lee YK, Yuk DY, Kim TI, Kim YH, Kim KT, Kim KH, Lee BJ, Nam SY, Hong JT: **Protective effect of the ethanol extract of *Magnolia officinalis* and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity.** *J Nat Med* 2009, **63**:274–282.
8. Lee JW, Lee YK, Lee BJ, Nam SY, Lee SI, Kim YH, Kim KH, Oh KW, Hong JT: **Inhibitory effect of ethanol extract of *Magnolia officinalis* and 4-O-methylhonokiol on memory impairment and neuronal toxicity induced by beta-amyloid.** *Pharmacol Biochem Behav* 2010, **95**:31–40.
9. Schuehly W, Paredes JM, Kleyer J, Huefner A, Anavi-Goffer S, Raduner S, Altmann KH, Gertsch J: **Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists.** *Chem Biol* 2011, **18**:1053–1064.
10. Freund TF, Katona I, Piomelli D: **Role of endogenous cannabinoids in synaptic signaling.** *Physiol Rev* 2003, **83**:1017–1066.
11. Alger BE: **Endocannabinoids at the synapse a decade after the *Dies Mirabilis* (29 March 2001): what we still do not know.** *J Physiol* 2012, **590**:2203–2212.
12. Ohno-Shosaku T, Tanimura A, Hashimoto-dani Y, Kano M: **Endocannabinoids and retrograde modulation of synaptic transmission.** *Neuroscientist* 2012, **18**:119–132.
13. Basu S, Dittel BN: **Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease.** *Immunol Res* 2011, **51**:26–38.
14. Pacher P, Mechoulam R: **Is lipid signaling through cannabinoid 2 receptors part of a protective system?** *Prog Lipid Res* 2011, **50**:193–211.
15. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA: **International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB<sub>1</sub> and CB<sub>2</sub>.** *Pharmacol Rev* 2010, **62**:588–631.
16. Lunn CA: **Updating the chemistry and biology of cannabinoid CB2 receptor-specific inverse agonists.** *Curr Top Med Chem* 2010, **10**:768–778.
17. Ashton JC, Glass M: **The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.** *Curr Neuropharmacol* 2007, **5**:73–80.

18. Rivers JR, Ashton JC: **The development of cannabinoid CB1 receptor agonists for the treatment of central neuropathies.** *Cent Nerv Syst Agents Med Chem* 2010, **10**:47–64.
19. Stella N: **Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas.** *Glia* 2010, **58**(9):1017–30.
20. Bisogno T, Di Marzo V: **Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders.** *CNS Neurol Disord Drug Targets* 2010, **9**:564–73.
21. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, Friedman H: **The cannabinoid system and immune modulation.** *J Leukoc Biol* 2003, **74**:486–96.
22. Di Marzo V: **Targeting the endocannabinoid system: to enhance or reduce?** *Nat Rev Drug Discov* 2008, **7**:438–55.
23. Palazuelos J, Davoust N, Julien B, Hatterer E, Aguado T, Mechoulam R, Benito C, Romero J, Silva A, Guzmán M, Nataf S, Galve-Roperh I: **The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis.** *J Biol Chem* 2008, **283**:13320–13329.
24. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, Ward AM, Hahn YK, Lichtman AH, Conti B, Cravatt BF: **Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation.** *Science* 2011, **334**:809–813.
25. Shohami E, Cohen-Yeshurun A, Magid L, Algali M, Mechoulam R: **Endocannabinoids and traumatic brain injury.** *Br J Pharmacol* 2011, **163**:1402–1410.
26. Mechoulam R, Shohami E: **Endocannabinoids and traumatic brain injury.** *Mol Neurobiol* 2007, **36**:68–74.
27. Tolón RM, Núñez E, Pazos MR, Benito C, Castillo AI, Martínez-Orgado JA, Romero J: **The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages.** *Brain Res* 2009, **1283**:148–54.
28. Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML: **Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.** *J Neurosci* 2005, **25**:1904–1913.
29. Benito C, Núñez E, Tolón RM, Carrier EJ, Rábano A, Hillard CJ, Romero J: **Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains.** *J Neurosci* 2003, **23**:11136–11141.
30. Pacher P, Mackie K: **Interplay of cannabinoid 2 (CB2) receptors with nitric oxide synthases, oxidative and nitrative stress, and cell death during remote neurodegeneration.** *J Mol Med (Berl)* 2012, **90**:347–351.
31. Gowran A, Noonan J, Campbell VA: **The multiplicity of action of cannabinoids: implications for treating neurodegeneration.** *CNS Neurosci Ther* 2011, **17**:637–644.
32. Benito C, Tolón RM, Castillo AI, Ruiz-Valdepeñas L, Martínez-Orgado JA, Fernández-Sánchez FJ, Vázquez C, Cravatt BF, Romero J: **Beta amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving Ppar- $\alpha$ , Ppar- $\gamma$  and Trpv1, but not Cb(1) or Cb(2) Receptors.** *Br J Pharmacol* 2012, **166**:1474–1489.
33. Correa F, Hernangómez M, Mestre L, Loría F, Spagnolo A, Docagne F, Di Marzo V, Guaza C: **Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF- $\kappa$ B.** *Glia* 2010, **58**:135–147.
34. Jüttler E, Potrovita I, Tarabin V, Prinz S, Dong-Si T, Fink G, Schwaninger M: **The cannabinoid dexamabinol is an inhibitor of the nuclear factor- $\kappa$ B (NF- $\kappa$ B).** *Neuropharmacology* 2004, **47**:580–592.
35. Chao LK, Liao PC, Ho CL, Wang EI, Chuang CC, Chiu HW, Hung LB, Hua KF: **Anti-inflammatory bioactivities of honokiol through inhibition of protein kinase C, mitogen-activated protein kinase, and the NF- $\kappa$ B pathway to reduce LPS-induced TNF $\alpha$  and NO expression.** *J Agric Food Chem* 2010, **58**:3472–3478.
36. Munroe ME, Arbiser JL, Bishop GA: **Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis.** *J Immunol* 2007, **179**:753–763.
37. Eikelenboom P, Veerhuis R, van Exel E, Hoozemans JJ, Rozemuller AJ, van Gool WA: **The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence.** *Curr Alzheimer Res* 2011, **8**:142–50.
38. Zotova E, Nicoll JA, Kalaria R, Holmes C, Boche D: **Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.** *Alzheimers Res Ther* 2010, **2**:1.
39. Trepanier CH, Milgram NW: **Neuroinflammation in Alzheimer's disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy?** *J Alzheimers Dis* 2010, **21**:1089–99.
40. Nimmo AJ, Vink R: **Recent patents in CNS drug discovery: the management of inflammation in the central nervous system.** *Recent Pat CNS Drug Discov* 2009, **4**:86–95.
41. Böhmendorfer M, Maier-Salamon A, Taferner B, Reznicek G, Thalhammer T, Hering S, Hüfner A, Schühly W, Jäger W: **In vitro metabolism and disposition of honokiol in rat and human livers.** *J Pharm Sci* 2011, **100**:3506–3516.
42. Schühly W, Hüfner A, Pferschy-Wenzig EM, Prettnner E, Adams M, Bodensieck A, Kunert O, Oluwemimo A, Haslinger E, Bauer R: **Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTb4-formation.** *Bioorg Med Chem* 2009, **17**:4459–4465.
43. Martínez M: *Las plantas medicinales de México.* 4th edition. Mexico City: Editorial Botas; 1959:343–347.
44. Ahmed SM, Abdelaleil AM: **Antifungal activity of extracts and sesquiterpene lactones from *Magnolia grandiflora* L. (Magnoliaceae).** *Int J Agric Biol* 2005, **7**:638–642.
45. Schühly W, Khan I, Fischer NH: **The ethnomedicinal uses of magnoliaceae from the southeastern United States as leads in drug discovery.** *Pharm Biol* 2001, **39**(Suppl 1):63–69.

doi:10.1186/1742-2094-9-135

**Cite this article as:** Gertsch and Anavi-Goffer: Methylhonokiol attenuates neuroinflammation: a role for cannabinoid receptors?. *Journal of Neuroinflammation* 2012 **9**:135.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

